Noven Pharmaceuticals, Inc.
11960 S.W. 144th Street
Miami
Florida
33186-5807
United States
Tel: 305-253-5099
141 articles about Noven Pharmaceuticals, Inc.
-
XELSTRYM™ (dextroamphetamine) transdermal system, CII, to be revealed as available soon at the 2023 American Professional Society of ADHD and Related Disorders (APSARD) Conference
1/10/2023
Noven Pharmaceuticals. Inc., (Noven) announced today that XELSTRYM™ (dextroamphetamine) transdermal system, CII, the first and only FDA-approved amphetamine patch for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in adults and pediatric patients six years and older, will be available across the U.S. for healthcare professionals to prescribe later in the first quarter of 2023.
-
NOVEN TO PARTICIPATE IN ANNUAL INTERNATIONAL CONFERENCE ON ADHD (CHADD)
11/10/2022
Noven Pharmaceuticals, Inc., ("Noven") a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc. focusing on the development of transdermal therapy, today announced that it will be participating in the 2022 Annual International Conference on ADHD (CHADD), November 17-19 in Dallas, Texas, USA.
-
NOVEN TO PRESENT DATA FOR: EXTRAPOLATING PEDIATRIC TRANSDERMAL ADHD TREATMENT EFFICACY DATA TO ADULT POPULATIONS
10/17/2022
Noven Pharmaceuticals. Inc. announced today it will present the results of two pharmacokinetic (PK) modeling datasets at the 36th American Psychiatric Nurses Association (APNA) annual conference in Long Beach, California October 19-22, 2022.
-
NOVEN TO PRESENT POSTER DATA AT THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY (AACAP) AND CANADIAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY (CACAP) CONFERENCE
10/11/2022
Noven Pharmaceuticals, Inc. today announced that it will present poster data related to its dextroamphetamine transdermal system (d-ATS) for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) at the annual American Academy of Child and Adolescent Psychiatry (AACAP) and Canadian Academy of Child and Adolescent Psychiatry (CACAP) conference October 17-22, 2022.
-
Noven to Present Pivotal Study Results for Investigational Dextroamphetamine Transdermal System for Pediatric ADHD Patients
4/27/2021
Noven Pharmaceuticals, Inc., (“Noven”) a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., today announced it will present the results of a multicenter, phase 2, laboratory classroom study which evaluated the safety and efficacy of its investigational dextroamphetamine transdermal system (“ATS”) in over 100 pediatric patients (ages 6-17 years) with ADHD at the 2021 virtual American Psychiatric Association
-
Noven Submits New Drug Application for Investigational Dextroamphetamine Transdermal System for ADHD
2/22/2021
Noven Pharmaceuticals, Inc., (“Noven”) a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., today confirmed it has submitted a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market its dextroamphetamine transdermal system (“ATS”).
-
SECUADO® (asenapine) Transdermal System, the First-and-Only Transdermal Patch for the Treatment of Adults with Schizophrenia, is Now Available in the U.S.
4/13/2020
Noven Pharmaceuticals, Inc., a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., today announced that SECUADO® (asenapine) transdermal system, the first-and-only transdermal patch formulation approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with schizophrenia, is now available by prescription in the U.S.
-
U.S. FDA Approves SECUADO® (asenapine) Transdermal System, the First-and-Only Transdermal Patch for the Treatment of Adults with Schizophrenia
10/15/2019
A transdermal patch may help to mitigate some of the challenges patients face with the management of their schizophrenia.
-
The patch is a once-per-day treatment that provides sustained concentrations of Secuado (asenapine), an atypical antipsychotic drug used to treat schizophrenia.
-
Noven Announces Appointment of Dr. Naruhito Higo as Chief Executive Officer
9/23/2019
Noven is a stand-alone operating subsidiary of Japan-based Hisamitsu Pharmaceutical Co., Inc., serving as Hisamitsu’s U.S. platform in prescription pharmaceuticals, and helping Hisamitsu bring the benefits of patch therapy to patients around the world.
-
Noven Announces Appointment of Andrew J. Purcell as Head of Marketing & Sales
7/11/2019
Key addition as Noven prepares for commercialization of HP-3070
-
Categorical Response and Clinical Relevance as Assessed in a Phase III Study of HP-3070 (Asenapine) Transdermal Patch for the Treatment of Schizophrenia to be Presented at the American Psychiatric Association 172nd Annual Meeting
5/20/2019
New Drug Application for HP-3070 under FDA review
-
Phase III Study Results for HP-3070 (Asenapine) Transdermal Patch for the Treatment of Schizophrenia to be Presented at the Society of Biological Psychiatry 74th Annual Meeting
5/16/2019
New Drug Application for investigational product HP-3070 under FDA review
-
Noven Files Patent Infringement Lawsuit Against Alvogen
11/8/2017
Alvogen is seeking approval to market and sell a generic version of Minivelle (estradiol transdermal system) prior to the expiration of two of Noven’s Orange Book listed patents (U.S. Patent Nos. 9724310 and 9730900).
-
Noven Appoints Mark Jackson As Vice President — Quality
2/6/2017
-
Noven Appoints Ralph Lipp, PH.D., As Vice President And Chief Scientific Officer
10/3/2016
-
Noven Announces Appointment Of Jeff Mihm To Its Board Of Directors
9/7/2016
-
Noven Appoints Dolores Calicchio As Vice President Of Human Resources
3/7/2016
-
Noven Announces Favorable Decisions In The Inter Partes Reviews Challenging Novartis AG’ Exelon Patch Patents
9/29/2015
-
Noven Appoints Scott Briggs As Vice President Of Marketing & Sales
3/30/2015